BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has reported E.P.S. of $-0.07 for its third fiscal quarter (ending September 30) versus $-0.19 for the same period a year ago — a decline of -63%. For the latest four quarters through September 30, E.P.S. were $-0.61 versus $-1.25 for the same period a year ago — a decline of -51%.
Recent Price Action
On 11/4/24, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock suffered a major decline of -12.8%, closing at $7.35. Moreover, exceptionally high trading volume at 593% of normal accompanied the decline. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -7.5% during the last week.
Current PriceTarget Research Rating
BCRX is expected to continue to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
BioCryst Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment